Mesenchymal Stem Cell‐Derived Extracellular Vesicles with High PD‐L1 Expression for Autoimmune Diseases Treatment

作者：Fang Xu, Ziying Fei, Huaxing Dai, Jialu Xu, Qin Fan, Shufang Shen, Yue Zhang, Qingle Ma, Jiacheng Chu, Fei Peng, Fangfang Zhou, Zhuang Liu, Chao Wang · 发表于：Advanced Materials · 年份：2021 · DOI：10.1002/adma.202106265 · 被引用次数：176 · 研究领域：Extracellular vesicles in disease、Immune cells in cancer、Immunotherapy and Immune Responses

Autoimmune diseases are the third most common disease influencing the quality of life of many patients. Here, a programmed cell death-ligand 1 + (PD-L1) mesenchymal stem cell (MSC) derived extracellular vesicles (MSC-sEVs-PD-L1) using lentivirus-mediated gene transfection technology is developed for reconfiguration of the local immune microenvironment of affected tissue in autoimmune diseases. MSC-sEVs-PD-L1 exhibits an impressive ability to regulate various activated immune cells to an immunosuppressed state in vitro. More importantly, in dextran sulfate sodium-induced ulcerative colitis (UC) and imiquimod-induced psoriasis mouse models, a significantly high accumulation of MSC-sEVs-PD-L1 is observed in the inflamed tissues compared to the PD-L1+ MSCs. Therapeutic efficiency in both UC and psoriasis mouse disease models is demonstrated using MSC-sEVs-PD-L1 to reshape the inflammatory ecosystem in the local immune context. A technology is developed using MSC-sEVs-PD-L1 as a natural delivery platform for autoimmune diseases treatment with high clinical potential.